Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2018
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 06 Nov 2018 Status changed from not yet recruiting to recruiting.
- 11 Oct 2018 Planned End Date changed from 1 Sep 2022 to 1 Oct 2022.
- 11 Oct 2018 Planned primary completion date changed from 1 Sep 2022 to 1 Oct 2022.